Lung infections caused by Mycobacterium abscessus are emerging worldwide and are very difficult to treat, because of the bacterium’s resistance to most classes of antibiotics. The research group led by Jakko van Ingen, clinical microbiologist at Radboudumc (Nijmegen, the Netherlands), has discovered that inhalation of an old antibiotic, tigecycline, may finally improve treatment outcomes of this severe infection, and is also likely less toxic when used by inhalation.
In the Journal of Antimicrobial Chemotherapy, the Radboudumc and Colorado State University group presents two mouse model experiments showing that inhaled tigecycline achieved eradication of M. abscessus from the lungs of all but one mouse. This dramatic effect is unprecedented for this bacterium, which is often called an “antibiotic nightmare.” The results of the current study suggest that development of an inhaled formulation of tigecycline may improve treatment outcomes of this severe lung infection.
Read more in the full article: